Protocol for a phase 3, randomized, double-blind clinical trial evaluating the safety and immunogenicity of the MVA-BN® vaccine against mpox in children aged 4 to less than 24 months in the Democratic Republic of the Congo: Data to guide future paediatric vaccination strategies.
- DOI
- 10.1016/j.vaccine.2026.128890
- Published
- 2026 Aug 30
- Container
- Vaccine
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.vaccine.2026.128890,
title = {Protocol for a phase 3, randomized, double-blind clinical trial evaluating the safety and immunogenicity of the MVA-BN® vaccine against mpox in children aged 4 to less than 24 months in the Democratic Republic of the Congo: Data to guide future paediatric vaccination strategies.},
author = {Tshilumba SM and Ruiz PM and Matuvanga TZ and Lemey G and Kimbulu P and Azoum MA and Salloum M and Kasereka G and Mitashi F and Bikioli F and Muteba D and Bisumba A and Van Damme P and Muhindo-Mavoko H and Jordan E and Van Geertruyden JP and Maketa V and Mitashi P and Larivière Y},
year = {2026},
journal = {Vaccine},
doi = {10.1016/j.vaccine.2026.128890},
url = {https://doi.org/10.1016/j.vaccine.2026.128890}
}RIS
TY - JOUR TI - Protocol for a phase 3, randomized, double-blind clinical trial evaluating the safety and immunogenicity of the MVA-BN® vaccine against mpox in children aged 4 to less than 24 months in the Democratic Republic of the Congo: Data to guide future paediatric vaccination strategies. AU - Tshilumba SM AU - Ruiz PM AU - Matuvanga TZ AU - Lemey G AU - Kimbulu P AU - Azoum MA AU - Salloum M AU - Kasereka G AU - Mitashi F AU - Bikioli F AU - Muteba D AU - Bisumba A AU - Van Damme P AU - Muhindo-Mavoko H AU - Jordan E AU - Van Geertruyden JP AU - Maketa V AU - Mitashi P AU - Larivière Y PY - 2026 JO - Vaccine DO - 10.1016/j.vaccine.2026.128890 UR - https://doi.org/10.1016/j.vaccine.2026.128890 ER -
APA
SM, T., PM, R., TZ, M., G, L., P, K., MA, A., M, S., G, K., F, M., F, B., D, M., A, B., P, V. D., H, M., E, J., JP, V. G., V, M., P, M., & Y, L. (2026). Protocol for a phase 3, randomized, double-blind clinical trial evaluating the safety and immunogenicity of the MVA-BN® vaccine against mpox in children aged 4 to less than 24 months in the Democratic Republic of the Congo: Data to guide future paediatric vaccination strategies.. Vaccine. https://doi.org/10.1016/j.vaccine.2026.128890
Source records
- pubmed · retrieved 2026-09-26T07:19:53.984Z